AGM
TGTX icon

Alpine Global Management’s TG Therapeutics TGTX Stock Holding History

Alpine Global Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,578
Closed -$137K – 393
2022
Q4 		$137K Buy
+11,578
New +$84K 0.05% 118
2021
Q2 		– Sell
-8,246
Closed -$397K – 369
2021
Q1 		$397K Buy
+8,246
New +$396K 0.04% 187

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alpine Global Management's TGTX Position: Q1 2023 in Review

Alpine Global Management sold out of TG Therapeutics (TGTX) in Q1 2023, closing a stake of 11,578 shares — an estimated $137K sold.

Alpine Global Management first reported a position in TGTX in Q1 2021 and held it in 2 quarters. The position peaked at $397K in Q1 2021. 214 funds tracked by Wall St. Rank hold TGTX as of Q1 2023.

  • Alpine Global Management reported no remaining TG Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 11,578 TG Therapeutics shares in Q1 2023, an estimated $137K.
  • Alpine Global Management first reported a position in TG Therapeutics in Q1 2021 and held it in 2 quarters.
  • Alpine Global Management's TG Therapeutics position peaked at $397K in Q1 2021.
  • 214 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.